Sandrine Faivre
Inserm(FR)Université Paris Cité(FR)Saint Louis University Hospital(US)Assistance Publique – Hôpitaux de Paris(FR)Centre de Recherche sur l'Inflammation(FR)Hôpital Saint-Louis(FR)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Lung Cancer Treatments and Mutations, Pancreatic and Hepatic Oncology Research, PI3K/AKT/mTOR signaling in cancer, Cancer Mechanisms and Therapy
Most-Cited Works
- → Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer(2005)1,150 cited
- → Current development of mTOR inhibitors as anticancer agents(2006)990 cited
- → Molecular basis for sunitinib efficacy and future clinical development(2007)703 cited
- → mTOR-targeted therapy of cancer with rapamycin derivatives(2005)616 cited
- → Targeting the TGFβ pathway for cancer therapy(2014)610 cited
- → Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation(2009)564 cited
- Oxaliplatin: mechanism of action and antineoplastic activity.(1998)